Literature DB >> 3685450

Pulmonary toxicity of a combination of low-dose doxorubicin and irradiation for inoperable lung cancer.

J Verschoore1, J L Lagrange, J L Boublil, J M Aubanel, B Blaive, J Pinto, M Namer.   

Abstract

In 1980, 27 patients with inoperable lung cancer (26 non-oat cell, one oat cell) were treated by split-course irradiation (40 Gy/10 fractions) plus concomitant low-dose chemotherapy (doxorubicin 10 mg/m2). Twenty-four of the 27 patients received the entire treatment course. Fifteen of the 27 patients were administered various chemotherapy protocols after a period of one month. Median survival was 16 weeks despite a 60% response rate. The lungs were the main site of complications (13 cases of radiation pneumonitis for the 24 patients), which occurred primarily when an objective response was obtained. These complications partially explain the poor results. Injection of doxorubicin during irradiation appears to have been a determining factor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3685450     DOI: 10.1016/s0167-8140(87)80149-4

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

1.  [The inhalation versus systemic prevention of pneumonitis during thoracic irradiation].

Authors:  J Pagel; M Mohorn; K H Kloetzer; M Fleck; T G Wendt
Journal:  Strahlenther Onkol       Date:  1998-01       Impact factor: 3.621

Review 2.  Pulmonary outcomes in survivors of childhood cancer: a systematic review.

Authors:  Tseng-Tien Huang; Melissa M Hudson; Dennis C Stokes; Matthew J Krasin; Sheri L Spunt; Kirsten K Ness
Journal:  Chest       Date:  2011-03-17       Impact factor: 9.410

3.  The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial.

Authors:  C Blomqvist; K Tiusanen; I Elomaa; P Rissanen; T Hietanen; E Heinonen; P Gröhn
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.